tislelizumab   Click here for help

GtoPdb Ligand ID: 9592

Synonyms: Bai Zean® | BGB-A317 | BGBA317 | hu317-1/IgG4mt2 | Tevimbra® | tislelizumab-jsgr
Approved drug Immunopharmacology Ligand
tislelizumab is an approved drug (China (2019), EMA (2023), FDA (2024))
Compound class: Antibody
Comment: Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody targeting the PD-1 immune checkpoint [5]. It contains an alternative hinge region compared to other IgG4 anti-PD-1 antibodies, and subsequently does not induce the crosslinking between PD-1 and FcγRI that is observed for existing agents and which is believed to negatively impact on anti-PD-1 antibody-mediated anti-cancer activity. This modified profile is predicted to enhance tislelizumab's clinical efficacy [5]. Like other anti-PD-1 antibodies tislelizumab acts to prevent the binding of the ligands PD-L1 and PD-L2 to PD-1. Tislelizumab is an immuno-oncology drug candidate that was originally developed by Beigene (see their patent US8735553B1 [4]), and Novartis announced that they had acquired the rights to tislelizumab in major markets outside China in January 2021.
Click here for help
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (China (2019), EMA (2023), FDA (2024))
International Nonproprietary Names Click here for help
INN number INN
10553 tislelizumab
Synonyms Click here for help
Bai Zean® | BGB-A317 | BGBA317 | hu317-1/IgG4mt2 | Tevimbra® | tislelizumab-jsgr
Database Links Click here for help
GtoPdb PubChem SID 340590223
Search PubMed clinical trials tislelizumab
Search PubMed titles tislelizumab
Search PubMed titles/abstracts tislelizumab